Information Provided By: 
Fly News Breaks for March 10, 2017
TTPH
Mar 10, 2017 | 08:26 EDT
As noted earlier, BMO Capital upgraded Tetraphase to Outperform from Market Perform. Analyst M. Ian Somaiya says that data on the company's eravacycline drug could support an early 2019 U.S. launch and generate peak sales of about $1B. The analyst adds that the company may announce an EU partner in 2H17, providing it with non-dilutive financing. Target to $10 from $6.
News For TTPH From the Last 2 Days
There are no results for your query TTPH
